Vildagliptin reduces specific TG species in T2D; GLP-1 blockade increases total TGsHow does a diabetes drug affect blood fats after eating? A small study finds clues

Diabetes Care Published April 3, 2026 Study authors: Xie Cong, White Jake B, Huang Weikun, Horowitz Michael, Rayner Christopher K, Verjans Johan W, Snel … PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Interpret small study on vildagliptin and TG species as preliminary physiological insight, not clinical guidance.

This randomized controlled trial examined the acute physiological effects of DPP-4 inhibition and GLP-1 receptor blockade on postprandial lipid metabolism. The study enrolled 15 participants with type 2 diabetes managed by diet and/or metformin. Participants received either vildagliptin (50 mg orally) followed by intravenous exendin(9-39) or saline, or placebo orally followed by intravenous saline, during intraduodenal lipid emulsion infusion and a mixed meal.

Treatment with vildagliptin alone reduced plasma concentrations of two specific triglyceride species: TG(54:4) and TG(54:5), both with P < 0.01. However, when endogenous GLP-1 was blocked with exendin(9-39) during vildagliptin treatment, total plasma triglycerides increased significantly (P < 0.001). Furthermore, 10 individual triglyceride species were elevated during this combined treatment, each with P < 0.05.

Safety and tolerability data were not reported. The study's key limitations include its very small sample size (n=15), short-term physiological design, and focus on surrogate lipid outcomes rather than clinical endpoints. The population was specific to patients managed with diet and/or metformin only.

For practice, this study provides mechanistic insight suggesting endogenous GLP-1 contributes to modulating postprandial triglyceride appearance during DPP-4 inhibition. However, it does not establish causation for clinical outcomes like cardiovascular risk. The findings are preliminary and require validation in larger, longer-term studies with clinical endpoints before any practice implications can be drawn.

After a meal, the fats in your blood rise and fall. For people with type 2 diabetes, this post-meal fat traffic can be messy and is linked to heart risks. Researchers wanted to understand how a common class of diabetes drugs might be involved in cleaning up that traffic. They gave 15 people with diet- or metformin-managed type 2 diabetes the drug vildagliptin, then infused fat directly into their intestines along with a meal to mimic real eating. They found the drug lowered the levels of two very specific types of fat particles in the blood. But the story got more complicated. When the researchers also gave a substance to block the body's natural GLP-1—a gut hormone boosted by the drug—the total amount of fat in the blood went up, and ten other specific fat particles increased as well. This suggests the body's own GLP-1, prompted by the drug, plays a role in managing these fats. It's a fascinating peek into human chemistry, but we need to be careful. This was a short-term study in a lab-like setting with only 15 people. The fats measured are detailed biological markers, not the standard cholesterol numbers from your doctor's visit. The study doesn't tell us if these changes are good, bad, or neutral for a person's actual health or heart risk down the line. It simply shows a connection that needs much more research.

What this means for you:

A diabetes drug changed specific blood fats in a small study, but the full health meaning is unknown.

Study Details

Study typeRct

EvidenceLevel 2

PublishedApr 2026

PMID41591292

View Original Abstract ↓

UNLABELLED: Glucagon-like peptide 1 (GLP-1) receptor agonists improve dyslipidemia and reduce cardiovascular risk in type 2 diabetes (T2D), but the role of endogenous GLP-1 in lipid metabolism remains unclear. We evaluated the effect of dipeptidyl peptidase 4 (DPP-4) inhibition on the response of plasma triglycerides (TGs) to intraduodenal lipid and a mixed meal, and the impact of GLP-1 receptor blockade with exendin(9-39) in T2D. Fifteen participants with T2D, managed by diet and/or metformin, were studied on three occasions in a double-blind, randomized, crossover design. Vildagliptin (50 mg) or placebo was administered orally (t = -60 min), followed by intravenous exendin(9-39) from t = -60 to 150 min on one of the two vildagliptin days or 0.9% saline on two other days. A lipid emulsion was infused intraduodenally (2 kcal/min, t = 0-120 min), followed by a mixed meal (t = 120-150 min). Plasma TG levels, quantified by liquid chromatography-tandem mass spectrometry, increased after lipid and meal, with most individual TGs corresponding to those in the lipid emulsion. Vildagliptin reduced TG(54:4) and TG(54:5) concentrations (each P < 0.01), without affecting total TGs. Blocking endogenous GLP-1 during vildagliptin treatment increased plasma total TGs (P < 0.001), associated with elevations of 10 individual TG species (P < 0.05 each). These outcomes suggest that endogenous GLP-1 contributes to the physiological modulation of postprandial TG appearance in T2D. ARTICLE HIGHLIGHTS: The contribution of endogenous glucagon-like peptide 1 (GLP-1) to postprandial lipid metabolism in type 2 diabetes (T2D) is poorly defined. The specific questions we wanted to answer were what is the effect of dipeptidyl peptidase 4 (DPP-4) inhibition on plasma triglyceride (TG) profiles during an intraduodenal lipid infusion and following a mixed meal in T2D, and how does blockage of endogenous GLP-1 signaling affect these responses? We found that plasma TGs increased after intraduodenal lipid infusion and the meal, with most species reflecting the infused lipid emulsion. Vildagliptin selectively reduced TG(54:4) and TG(54:5) species, whereas exendin(9-39) increased total TGs and 10 individual TG species. The implications of our finding are that endogenous GLP-1 plays a physiological role in the regulation of postprandial lipid handling in T2D.

Vildagliptin reduces specific TG species in T2D; GLP-1 blockade increases total TGsHow does a diabetes drug affect blood fats after eating? A small study finds clues

Study Details

Sitagliptin and liraglutide superior for CGM targets in type 2 diabetes

Two diabetes drugs outperform others in long-term glucose control

Clinical research that matters. Delivered to your inbox.

Vildagliptin reduces specific TG species in T2D; GLP-1 blockade increases total TGsHow does a diabetes drug affect blood fats after eating? A small study finds clues

More on Type 2 Diabetes

Study Details

Sitagliptin and liraglutide superior for CGM targets in type 2 diabetes

Two diabetes drugs outperform others in long-term glucose control

Clinical research that matters. Delivered to your inbox.

Related in Nutrition & Obesity Medicine

From Other Specialties